title: [The effect of CD4+ CD25+ regulatory T cell inactivation combined with levofloxacin on murine tuberculosis].
abstract: OBJECTIVE
  To investigate the effects of inactivation of CD(4)(+)CD(25)(+) regulatory T cells (Treg) combined with the administration of levofloxacin (LFX) on the cellular immune response of murine tuberculosis.
  
  
  METHODS
  Inactivation of Treg was achieved by intraperitoneal injection of anti-CD(25), clone PC61. Female C57BL/6 mice were divided into 4 groups, PC61 alone, LFX alone, PC61 plus LFX, and the control, with 19 mice in each group. The LFX group and the control group were treated with rat-IgG isotope control. Mice were inoculated with H(37) Rv (1 x 10(6) CFU) via the tail vein 3 days later. From the 2nd day, the LFX group and the PC61 plus LFX group received intragastric administration of LFX at 200 mg x kg(-1) x d(-1) per mouse for 45 days. Blood and spleen Tregs were measured by flow cytometry. The cellular immune response and pulmonary histopathology at different time points were also evaluated after infection.
  
  
  RESULTS
  At the 10th and 30th day, the ratio of CD(4)(+)CD(25)(+)/CD(4)(+)T cells in the spleen was (30 +/- 4)% and (17.3 +/- 1.6)% respectively in the control group, (21 +/- 4)% and (16.1 +/- 1.3)% respectively in the PC61 group, (44 +/- 6)% and (24.7 +/- 2.0)% respectively in the LFX group, (24 +/- 3)% and (10.4 +/- 1.0)% respectively in the PC61 plus LFX group. The differences were significant between groups (q = 3.62 - 5.56, P < 0.05), but the difference between the PC61 plus LFX group and the PC61 group at the 10th day. Same results were obtained from the peripheral blood. PC61 plus LFX therapy resulted in BCG specific cytokine response (IL-17, IFN-gamma, TNF-alpha) from murine spleen cells at the 10th and the 30th day, and also in milder pathologic changes and the lowest mortality.
  
  
  CONCLUSIONS
  The cellular immune response was enhanced by Treg inactivation and LFX therapy, which decreased the pathologic changes and the mortality of murine tuberculosis.
authors.affiliation: Renmin Hospital of Wuhan University, Wuhan 430060, China.
authors.forename: Xin-Deng
authors.initials: XD
authors.lastname: Tong
authors.forename: Mei-Zhong
authors.initials: MZ
authors.lastname: Li
authors.forename: Bo-Ping
authors.initials: BP
authors.lastname: Zhou
authors.forename: Xin-Chun
authors.initials: XC
authors.lastname: Chen
authors.forename: Yan-Zhong
authors.initials: YZ
authors.lastname: Peng
authors.forename: Xiao-Hua
authors.initials: XH
authors.lastname: Yue
authors.forename: Ji-Zhou
authors.initials: JZ
authors.lastname: Gou
authors.forename: Zhi-Jiao
authors.initials: ZJ
authors.lastname: Tang
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D005260:Female; D064704:Levofloxacin; D051379:Mice; D008810:Mice, Inbred C57BL; D015242:Ofloxacin / Q000627:therapeutic use*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000276:immunology
chemical_list: D000900:Anti-Bacterial Agents; D064704:Levofloxacin; D015242:Ofloxacin